• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Advisory Committees

  • Print
  • Share
  • E-mail

Briefing Information for the February 8, 2011 Meeting of the Oncologic Drugs Advisory Committee

 

Persons with disabilities having problems accessing the PDF file(s) below may call (301) 796-3634 for assistance
 
 
FDA
 
Disclaimer
 
Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. § 552).
 
FDA Briefing Information for the February 8, 2011 Meeting of the Oncologic Drugs Advisory Committee (PDF – 2.47MB)
 
 
Eli Lilly and Co.
 
Disclaimer
 
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
 
Eli Lilly Briefing Information, Erbitux (cetuximab), for the February 8, 2011 Meeting of the Oncologic Drugs Advisory Committee (PDF – 1.67MB)
 
GlaxoSmithKline
 
Disclaimer
 
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
 
GSK Briefing Information, Bexxar (tositumomab and Iodine I 131 tositumomab), for the February 8, 2011 Meeting of the Oncologic Drugs Advisory Committee (PDF – 5.08MB)
 
GSK Briefing Information, Arranon (nelarabine) Injection, for the February 8, 2011 Meeting of the Oncologic Drugs Advisory Committee (PDF – 407KB)
 
Genzyme Corp.
 
Disclaimer
 
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
 
Genzyme Briefing Information, Clolar (clofarabine), for the February 8, 2011 Meeting of the Oncologic Drugs Advisory Committee (PDF – 683KB)
 
Amgen, Inc.
 
Disclaimer
 
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
 
Amgen Briefing Information, Vectibix (panitumumab), for the February 8, 2011 Meeting of the Oncologic Drugs Advisory Committee (PDF – 1.05MB)
 
Novartis Pharmaceuticals Corp.
 
Disclaimer
 
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
 
Novartis Briefing Information, Gleevec (imatinib mesylate) Tablets, for the February 8, 2011 Meeting of the Oncologic Drugs Advisory Committee (PDF – 245KB)